Position statement on the use of biosimilars in inflammatory bowel disease.
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_36BBB90B8A2E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Position statement on the use of biosimilars in inflammatory bowel disease.
Périodique
Swiss medical weekly
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
02/12/2019
Peer-reviewed
Oui
Volume
149
Pages
w20148
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Publication Status: epublish
Résumé
Biologics are effective and have a good safety profile in the treatment of inflammatory bowel disease. Biosimilars have recently become available as treatment option. They are biological agents that are highly similar to the original biologic compound in their structure, biological activity, efficacy and safety. This position paper summarises current knowledge on biosimilars and presents its statements on regulatory issues and clinical situation in order to provide clinicians adequate information for them to reach informed and appropriate shared decision-making with their patients.
Mots-clé
Antibody Formation, Biosimilar Pharmaceuticals/therapeutic use, Clinical Trials as Topic, Drug Approval/legislation & jurisprudence, Drug Prescriptions, Drug Substitution, Humans, Inflammatory Bowel Diseases/drug therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
04/01/2020 12:59
Dernière modification de la notice
13/04/2024 7:10